Loiasis Clinical Trial
Official title:
Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 3- or 5- Day Course of Levamisole 2.5 mg/kg in Subjects With Loa Loa Microfilaremia
The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
Onchocerciasis and loiasis are parasitic diseases caused by Onchocerca volvulus and Loa loa, respectively. Onchocerciasis is endemic in 31 African countries, parts of South America, and Yemen, affecting around 37 million people, while loiasis is present in Central Africa, infecting approximately 15 million individuals. Both diseases are associated with severe complications and increased mortality. African countries have implemented mass drug administration (MDA) programs using ivermectin to combat onchocerciasis. However, co-endemic loiasis poses challenges due to the risk of severe adverse events. Current strategies involve alternative treatments and chemoprophylaxis to accelerate onchocerciasis elimination. The project aims to evaluate the use of levamisole as an alternative treatment. This project will assess the safety and efficacy of administering levamisole for 3 and 5 days to reduce Loa microfilarial density. Previous research demonstrated the safety of a single dose of levamisole but indicated the need for longer treatment regimens to achieve a significant reduction in Loa microfilarial density. The project aims to test whether 3- and 5-day levamisole regimens induce an acceptable safety profile and a stronger reduction in Loa microfilarial density. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02644525 -
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
|
Phase 2 | |
| Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
| Completed |
NCT05085665 -
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
|
Phase 4 | |
| Active, not recruiting |
NCT04258670 -
Spontaneous Antigenemia in Loiasis
|
||
| Completed |
NCT04049630 -
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04049851 -
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
|
Phase 2 | |
| Not yet recruiting |
NCT06350851 -
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
|
N/A | |
| Completed |
NCT01111305 -
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
|
Phase 2 |